Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Published on: Feb 14, 2024

A dynamic convergence of economic, legislative, scientific, and technological influences is molding the future of the healthcare industry – with implications for biotech companies. Healthcare environments are becoming increasingly complex as drug developers increasingly make the transition to next-generation therapeutics, driving demand for clinical innovation. Against this backdrop, the industry continues to pioneer new approaches to engaging with patients, clinical trial teams, and healthcare providers. During a recent panel discussion, Goldman Sachs and Parexel shared perspectives on emerging trends and high-level developments to help biotechs plan their short- and near-term strategies.

Read the full article

1f19cd397a348ae134fbb8b153b1f4f6.jpg

Get more insights from our recent panel discussion with Goldman Sachs, entitled “Decoding Healthcare’s Future: A comprehensive analysis of investment, clinical research and regulatory dynamics.”

Watch the full video

The views and opinions expressed by the authors are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs, or Parexel, for you to take any action.

Return to Insights Center

Related Insights

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Blog

Preparing for a new era in European Market Access

Jul 22, 2022

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Playbook

Streamlining success: How integrated evidence planning transforms asset development

Feb 27, 2025

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Blog

Overcoming risks in Phase 3 trials to accelerate time to market

Jan 22, 2025

Blog

Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development

Jan 22, 2025

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Article

Three strategies for articulating a coherent product value story

Dec 18, 2021

Playbook

Early-phase development strategies for navigating regulatory complexity in the EU

Apr 29, 2024

Article

How emerging biotechs can enter the Chinese market and prosper

Jan 18, 2022

Related Insights

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Blog

Preparing for a new era in European Market Access

Jul 22, 2022

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Playbook

Streamlining success: How integrated evidence planning transforms asset development

Feb 27, 2025

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Show more